Title of study

    The Consortium for the Early Identification of Alzheimer's Disease

    Acronym for cohort

    CIMA-Q

    Name of Principal Investigator - Title

    Prof

    Name of Principal Investigator - First name

    Jean-Paul

    Name of Principal Investigator - Last name

    Soucy

    Address of institution -Institution

    McGill University

    Address of institution - Street address

    Address of institution - City

    Address of institution - Postcode

    Country

    Canada

    Website

    Funding source

    CQDM and Brain Canada (with financial support of Health Canada)

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Alzheimer's disease and other dementias

    Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

    To advance knowledge about Alzheimer's disease with the mission to develop tools permitting its earliest detection.

    Q2b. What distinguishes this case-control study from other studies?

    Direct comparison of brain and retinal amyloid content.

    Q3a. i) Number of publications that involve use of your cohort to date

    0

    Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

    We hope to validate an easy-to-implement retinal scanning technique as an early test for AD detection.

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    55

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    85

    Q4b. Study criteria: what are the inclusion criteria?

    Q4c. Study criteria: what are the exclusion criteria?

    Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

    1-1,000

    Q5b. What is the expected number of control participants?

    Q6a. Please describe what measures are used to characterise participants

    Clinical, cognitive, neuroimaging meausures, retinal fluorescence imaging

    Q6b. Are there additional measures for participants with the clinical disorder?

    No

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    If YES please specify

    Q7. What is the study design?

    Cross sectional survey

    Q8. Are your cases matched by

    Cogntive function

    Q9a. Does your study includes a specialised subset of control participants?

    Q9b. If your study includes a specialised subset of control participants please describe

    Q10a. Is data collection for this study

    Data collection ongoing

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    No

    Q11. Are data collected

    Only through the study

    Q12. Is there a system in place to enable re-contact with patients for future studies?

    Q13a. Please give information on data stored in a database (1)

    Data summarised in database

    % Available

    100

    Q13a. Please give information on data stored in a database (2)

    No

    % Available

    Q13a. Please give information on data stored in a database (3)

    No

    % Available

    Q13a. Please give information on data stored in a database (4)

    No

    % Available

    Q13a. Please give information on data stored in a database (5)

    No

    % Available

    Please specify language used

    % Available

    100

    Q13b. Please give information on how data is held as individual records

    No

    % Available

    Q14a. Are data available to other groups?

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Q15. What data sharing policy is specified as a condition of use?

    Q16a. Are tissues/samples/DNA available to other groups?

    Q16b i) If yes, please describe below

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Q17. Is information on biological characteristics available to other groups?

Types: Case Control Studies
Member States: Canada
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF